Daiichi Sankyo Co Ltd - Stock Quote DSKYF
Morningstar's Daiichi Sankyo Co Ltd Stock Analysis
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Daiichi Sankyo Co Ltd's Company Profile
Daiichi Sankyo Co Ltd is a Japanese pharmaceutical company. It focuses on research and development for bringing up forth novel therapies in oncology, including immune oncology, with further focus on new areas, such as pain management, neurodegenerative diseases, heart and kidney diseases. Daiichi, through the pharmaceutical technology platform, develops processes for manufacturing of quality pharmaceuticals that meet desired efficacy and safety parameters. Daiichi is involved in process technology, biotechnology, formulation technology, analytical and quality evaluation technology. Its products brand includes PRALIA, MOVANTIK, LIXIANA, levofloxacin, Injectafer, and others. The company has its business operations in Europe, North America, and Japan. Most of its revenue comes from Japan.
Tokyo, 103-8426, Japan